First Light Asset Management LLC Sells 339,604 Shares of Guardant Health, Inc. (NASDAQ:GH)

First Light Asset Management LLC trimmed its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 52.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 309,389 shares of the company’s stock after selling 339,604 shares during the quarter. First Light Asset Management LLC’s holdings in Guardant Health were worth $9,452,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $26,000. SBI Securities Co. Ltd. bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $43,000. Kimelman & Baird LLC bought a new stake in shares of Guardant Health during the fourth quarter valued at approximately $58,000. NewEdge Advisors LLC grew its stake in Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock worth $59,000 after purchasing an additional 230 shares during the period. Finally, Quantbot Technologies LP bought a new position in Guardant Health in the fourth quarter worth $80,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Stock Up 1.9 %

Shares of NASDAQ GH opened at $48.30 on Monday. The firm’s 50-day moving average price is $43.37 and its 200-day moving average price is $37.42. The company has a market cap of $5.96 billion, a PE ratio of -13.57 and a beta of 1.45. Guardant Health, Inc. has a 52-week low of $17.52 and a 52-week high of $50.89.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. As a group, equities research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on GH shares. Canaccord Genuity Group upped their target price on shares of Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. Piper Sandler upped their target price on shares of Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Stifel Nicolaus upped their target price on shares of Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Guggenheim reaffirmed a “buy” rating and issued a $56.00 target price on shares of Guardant Health in a research report on Monday, February 24th. Finally, The Goldman Sachs Group upped their target price on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Twenty analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $49.00.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.